Help the Future of Cancer Treatment

Volunteering for a clinical trial is a contribution to the future of medicine that only you can make.

A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination with Daratumumab SC and Lenalidomide (Tal-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy

Primary Investigator
Pianko, Matthew
Status
OPEN TO ACCRUAL
Phase
III
NCT Number
NCT05552222
UM Number
2025.066
Age Group
Adults
Management Group
CTSU - Oncology
Oncology Group
Hematological Malignancies
ID (Protocol)
53916
Secondary Protocol No
HUM00271528
Scope
Unspecified
Sponsor Type
Industry
Disease Site
Multiple Myeloma
Summary
The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).

Eligibility: Inclusion Criteria
  •   * Have a diagnosis of multiple myeloma according to the International Myeloma Working Group (IMWG) diagnostic criteria
  •   * Be newly diagnosed and not considered a candidate for high-dose chemotherapy with autologous stem cell transplant (ASCT) due to: ineligible due to advanced age OR; ineligible due to the presence of comorbid condition(s) likely to have a negative impact on tolerability of high-dose chemotherapy with ASCT OR; deferral of high-dose chemotherapy with ASCT as initial treatment
  •   * Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2
  •   * A participant must agree not to be pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 6 months after the last dose of study treatment
  •   * A participant must agree not to plan to father a child while enrolled in this study or within 100 days after the last dose of study treatment
Exclusion Criteria
  •   * Received any prior therapy for multiple myeloma or smoldering myeloma other than a short course of corticosteroids (not to exceed total of 160 milligrams [mg] dexamethasone or equivalent). In addition, received a cumulative dose of systemic corticosteroids equivalent to greater than or equals to (>=) 20 mg of dexamethasone within 14 days before randomization
  •   * Had plasmapheresis within 28 days of randomization
  •   * Had a stroke, transient ischemic attack, or seizure within 6 months prior to randomization
  •   * Known allergies, hypersensitivity, or intolerance to teclistamab or talquetamab excipients
  •   * Known contraindications to the use of daratumumab or lenalidomide per local prescribing information
  •   * Myeloma Frailty Index of >=2 with the exception of participants who have a score of 2 based on age alone